There are two ways to think about this report from I-MAK that calculated that just four medicines -- Humira, Rituxan, Avastin and Lantus -- made more than $150 billion in
Reading Bob Herman’s new STAT piece about the newest PBM tactic -- something called “rebate credits” -- is kind of tough sledding. The source materials aren’t made available, so his
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv